3 news items
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
AUPH
4 Jun 24
and management team have been taking a range of actions to position the Company for sustainable success and build value for shareholders, while
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024
AUPH
14 May 24
sustained complete renal response and reductions in steroid use over three years of treatment, compared to MMF and steroids alone," said Dr. Greg Keenan
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
AUPH
2 May 24
now includes long-term data from a post-hoc analysis of the AURORA 2 extension study showing that patients receiving LUPKYNIS achieved sustained
- Prev
- 1
- Next